NCT01741116View on ClinicalTrials.gov

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

October 31, 2016

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

TKI258

Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal

Trial Locations (2)

110999

Korean Cancer Study Group, Seoul

136-705

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Korean Cancer Study Group

OTHER

NCT01741116 - Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter